Bone Biologics Corp (BBLG)

[mc73]

Why is this running...anyone? Bueller?

[Triple nickle]

Moving along

[Monksdream]

BBLG new 52 week low

[rbtree]

That's true, and if it's been going on, it can now proceed with redoubled speed, assuming they didn't also reduce the a/s at the same ratio.....

I see that there's an offering planned... and, at today's price, the amount of shares needed with be close to 4x the amount as of the offering date. due to the precipitous price decline. The dilution will be devastating.

Yikes.

[Awl416]

Ya can’t fight dilution….

[rbtree]

Split adjusted, I see this was over $150 early in 2022....Yikes. Is there anything worth looking at with the company? Why has it dropped so much? Was it shorted?
I just heard about it, and was wondering. I know nothing of the company. Sorry, folks.

[Triple nickle]

Keep going baby

[Jess070283]

Will this squeeze today? Hmmmm

[splintered sunlight]

Right on!!!!

[Triple nickle]

Hmmmm grabbed the dip

[urge2surge]

Shorts exiting on low outstanding shares here. Hold your shares. Weekly chart looking solid for major run up. Gap up at 80s. Probably won't fill without news but 50-60 possible.
Long way out for a r s..

[The Night Stalker]

RS bound

[urge2surge]

Looks like a panelrequest or r s to satisfy NASDAQ. Only 17 million outstanding and 1 for 20 should give the outstanding at sub 1 million. The 80s gap will necessitate a $16 ballpark to fill. MMS trying to create panic selling to cover but fuck them. If they initiate a r s soon they'll be in a big dog pile situation. Hold your shares as the squeeze thereafter will be epic!!

[The Night Stalker]

dip

[Triple nickle]

Bottom is in
Imo

[Triple nickle]

Added a bunch

[Triple nickle]

Cheap

[The Night Stalker]

cheap

[The Night Stalker]

cheap

[Triple nickle]

Took a starter here

[81vette]

Only a few trades a year look this good,super low risk/insane high reward,40% insider,bulls loading last 6 days macd flipped to buy,big news is coming with all this buying and bid humping and short covering,102k shares short,trial starting,manufacturers contract and supply agreement inbound,long target is $4.90,I can’t find a down side with book pps .42 and cash pps .51,not optionable so no less mm games,EF Hutton buy rating with 2.25 target,6 institutions new buys,sabby up 1139% FOLLOW THE $ FOR ME

[81vette]

9X relative vol,buckle up on this babe

[makinezmoney]

$BBLG: Trying to bounce higher at 0.24


On watch here amigos



GO $BBLG

[IPO$]

How is Wallacebeth Capital’s track record on its IPO’s?

[crudeoil24]

Revenues chit the bed ! <> $0.00

[glens0]

BBLG .34 New price target out $7.50

[crudeoil24]

PT > 8.00 > Bone Biologics Zack's Small Cap Research Issues Note With $8 Valuation Target On Stock.
11:02 am ET March 18, 2022

[Jack_Bauer_Investing]

$BBLG FDA accepted pilot study from Australia, multibillion-dollar spinal fusion market, targeted bone regeneration, exclusive global license to its proprietary tech & heavy insider ownership - biotech stock to watch

https://pennystocks.today/biotech-stocks-to-watch-ahead-of-news/

[KeepOn]

Bone Biologics Up 82% on Conference Presentation

https://www.marketwatch.com/story/bone-biologics-up-82-on-conference-presentation-271641843405

[crudeoil24]

Bone Biologics Shares Spike Following Recent Zack's Small Cap Research Report Showing $8 Valuation Target

[jackson73]

Nice 7am pm pop to 9.00

[TheFinalCD]

CONGRAT$ BBLG Nov 01 2021 5.48 0.48 9.6% 5.2013 5.6796 5.09 550,033

[crudeoil24]

Bone Biologics Shares Up 60% Premarket; An Amended 13D Filing on Monday from Hankey Capital, LLC Showed a 69% Stake.


BBLG

[crudeoil24]

Bone Biologics Corporation is a medical device company. The Company is focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX. The NELL-1/DBX combination product is an osteostimulative recombinant protein that provides target specific control over bone regeneration. Its platform technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It develops a platform technology through laboratory and small and large animal research to generate the applications across fields of use. The platform technology is its human protein, known as NELL-1, a skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration.

BBLG